

## REMARKS/ARGUMENT

### Description of Amendments

Applicant has amended claim 18, added claim 26, and cancelled claim 17. As amended, claims 1, 2, 4, 6, 9-16, 18, and 26 are now pending and under examination, and claims 3, 5, 7, 8, and 19-25 are withdrawn.

The amendments to claim 18 are supported by the application as originally filed (see, for example, paragraph [0077]). New claim 26 is also supported by the application as originally filed (see, for example, paragraph [0065] and Figure 4C).

### Finality of Office Action

Applicant respectfully submits that the present Office Action does not satisfy the requirements of the MPEP. In the Office Action, the Examiner rejected claim 6 but provided no explanation for the rejection. The MPEP requires that the Examiner properly communicate the basis for a rejection so that Applicant can be given fair opportunity to reply (MPEP 706.02(j)). The MPEP further requires that where a claim is refused for any reason relating to the merits thereof the ground of rejection should be fully and clearly stated (see MPEP 707.07(d)).

Since no explanation was given for the rejection of claim 6, Applicant has not been given a fair opportunity to reply and is in a difficult position to decide how to proceed. One of Applicant's options is to appeal the rejection of claim 6, but Applicant cannot evaluate the strengths and weaknesses of the rejection and is not in a position to argue against the rejection.

**Therefore, Applicant respectfully requests that the Office Action be withdrawn and a new Office Action be issued stating the basis for the rejection of claim 6.**

### Information Disclosure Statement of Sep. 1, 2004

The Examiner refused to consider the Information Disclosure Statement (IDS) allegedly filed on Sep. 1, 2004 on the ground that the IDS does not include a 1449 form. Applicant's file does not indicate that an IDS was filed on Sep. 1, 2004. May Applicant

request the Examiner to please send a copy of the alleged IDS to Applicant so that Applicant can properly address this issue?

Rejections under 35 U.S.C. §102

Claim 17 was rejected under 35 U.S.C. §102(e) as being anticipated by *Ding* (U.S. Patent Publication 2006/0089705). The cancellation of claim 17 renders this rejection moot.

Claims 1, 2, 6, and 10-18 were rejected under 35 U.S.C. §102 as being anticipated by *Tartaglia* (U.S. Patent 5,700,286). The cancellation of claim 17 renders its rejection moot. The rejection of claim 6 is improper because the Office Action provided no explanation for the rejection. For the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejection of claims 1, 2, 10-16, and 18.

One disadvantage of a prior art drug eluting stent is that when the stent is expanded, the drug-coated stent surfaces are stretched, causing uneven distribution of coated drug on stent surfaces. One object for the present invention is overcome this disadvantage of the prior art.

The claimed invention includes independent drug-loaded elements, which are not stretched when the stent structure expands from the unexpanded condition to the expanded condition. Consequently, the expansion of the stent structure does not cause an uneven distribution of coated drug.

*Tartaglia* discloses an expandable stent structural member (22) and a planar sheet or film (24) of polymeric material that is wrapped around the stent (column 4, lines 19-49). The Examiner contended that the planar sheet or film (24) is the independent drug-loaded elements of the claimed invention. Applicant respectfully disagrees.

*Tartaglia* does not disclose **independent** drug-loaded elements. Instead, it discloses only a single planar sheet or film (24). The single planar sheet or film (24) cannot be **independent** drug-loaded elements.

In the Office Action of November 7, 2006, the Examiner contended:

“the slits 30 produce independent elements even through they are attached at a first end. Applicant’s claim language does not exclude this configuration. The free ends are allowed to move independent from the others and are therefore considered independent. *Tartaglia* states, ‘the film of polymeric material also has a free end 28,

and can have one or more slits 30 in the polymeric film transverse to the axis 32 of the stent to accommodate possible uneven expansion of the underlying stent structural member (4:37 et seq.).”

Apparently, the Examiner believed that the so-called “independent elements,” allegedly produced by the slits (30), have free ends and are therefore independent.

Applicant respectfully disagrees with the Examiner’s reading of *Tartaglia*. Contrary to the Examiner’s contention, the slits (30) of *Tartaglia* do not produce “independent elements” that have free ends. As cited by the Examiner, *Tartaglia* discloses that the film (24) has only one free end (28); *Tartaglia* does not disclose a plurality of free ends. As shown in Figures 3 and 4, the slits (30) do not reach the free end (28) of the film (24) to produce a plurality of free ends. Therefore, both ends of the alleged “independent elements” are attached to one another.

Additionally, elements that are attached only at one end are not independent. The dictionary definition of “independent” is “not influenced.” Elements that are attached at one end are not independent, because they are influenced by one another because of the attachment.

Furthermore, the independent drug-loaded elements of the claimed invention are not stretched when the stent structure expands from the unexpanded condition to the expanded condition. In *Tartaglia*, the planar sheet or film (24), which is wrapped around the stent structural member (22), will inevitably be subject to a stretching force when the stent structural member (22) expands, and this stretching force will stretch the planar sheet or film (24) to some extent, potentially causing uneven distribution of coated drug.

In view of the above remarks, Applicant respectfully submits that *Tartaglia* does not teach the limitation of independent drug-loaded elements and the limitation that the sleeve is not stretched when the stent structure expands from the unexpanded condition to the expanded condition. Accordingly, *Tartaglia* does not anticipate independent claims 1 and 18. Dependent claims 2 and 10-16 are also not anticipated because they depend from claim 1.

Rejection under 35 U.S.C. §103(a)

Claims 1, 2, 4, and 9-18 were rejected under 35 U.S.C. §103(a) as being unpatentable over *Williams* (U.S. Patent 5,707,385) in view of *Tartaglia*. The cancellation of claim 17 renders its rejection moot. For the following reasons, Applicant respectfully requests reconsideration and withdrawal of the rejection.

*Williams* discloses an expandable stent (16) stent and an expandable membrane (5) that is mounted on the expandable stent (see Abstract). When the stent (16) is expanded, the expandable membrane (5) is stretched (see claim 1 and column 2, lines 30-41). The Examiner conceded that *Williams* does not disclose a sleeve that includes independent drug-loaded elements, but contended that *Tartaglia* teaches independent elements separated by slits (30).

Applicant respectfully disagrees with the Examiner's reading of *Williams* and *Tartaglia*. First, as discussed above, *Tartaglia* does not teach independent elements separated by slits (30).

Second, neither *Williams* nor *Tartaglia* teaches the limitation that the sleeve is not stretched when the stent structure expands from the unexpanded condition to the expanded condition. As explicitly taught by *Williams*, its expandable membrane (5) is designed to stretch when the stent (16) expands from the unexpanded condition to the expanded condition (see claim 1 and column 2, lines 30-41). In *Tartaglia*, the planar sheet or film (24), which is wrapped around the stent structural member (22), will inevitably be subject to a stretching force when the stent structural member (22) expands, and this stretching force will stretch the planar sheet or film (24) to some extent, potentially causing uneven distribution of coated drug.

In view of the above remarks, the cited art does not teach each and every limitation of independent claims 1 and 18. Accordingly, independent claims 1 and 18 are patentable over the cited art. Dependent claims 2, 4, and 9-16 are also patentable because they depend from patentable claim 1.

Patentability of New Claim 26

New claim 26 is patentable because it depends from patentable claim 1. In addition, claim 26 recites the limitation that “each of the independent drug-loaded elements is releasably adhered to the outer surface of the stent structure in the unexpanded condition.” This limitation is not taught or suggested by the cited art.

In light of the foregoing remarks, this application is considered to be in condition for allowance, and early passage of this case to issue is respectfully requested. If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 07-1850.

Respectfully submitted,

Date: January 8, 2007

/Song Zhu, Reg. No. 44,420/

---

Squire, Sanders & Dempsey L.L.P.  
One Maritime Plaza  
Suite 300  
San Francisco, CA 94111  
Facsimile (415) 393-9887  
Telephone (415) 954-0241  
[szhu@ssd.com](mailto:szhu@ssd.com)

---

Song Zhu, Ph.D.  
Attorney for Applicant  
Reg. No. 44,420